No new cyber incidents in Kalaris and AN2 SEC filings; keep watch for follow-up 8-Ks
Published Mar 17, 2026, 8:21 PM UTC
Key entities
TLDR
No escalation: today’s Kalaris 10-K and AN2 10-K/8-K do not, as posted, disclose cybersecurity incidents or material operational impacts; monitor for amended filings or follow-up 8-Ks within 72 hours and check company press pages for updates.
Why this matters
SEC index entries for Kalaris 10-K and AN2 8-K/10-K were posted today.
What changed
- New SEC filings posted: Kalaris Therapeutics 10-K and AN2 Therapeutics 8-K/10-K.
- As indexed, none indicate new cyber incidents or material operational impacts.
Topic context
Use this page when you need a tighter view of zero-days, ransomware, outage-linked cyber risk, and critical-infrastructure incidents without reading every advisory feed directly. Key angles: ransomware, zero-day, cve-, vulnerability.
Summary
Based on today’s SEC index entries for Kalaris Therapeutics (10-K) and AN2 Therapeutics (10-K and 8-K), there are no newly disclosed cybersecurity incidents, ransomware events, or material operational disruptions affecting critical infrastructure or systemic cyber risk; maintain routine monitoring for amendments or subsequent company notices.